SAN FRANCISCO — Researchers have achieved what many consider the “holy grail” of oncology: the ability to reprogram a patient’s immune system to fight cancer without ever removing a single cell from their body.
In a study published in Nature, a collaborative team from UCSF, Gladstone Institutes, Duke University, and the Innovative Genomics Institute demonstrated a method to create CAR-T cells in vivo (inside the body), potentially rendering current million-dollar lab procedures obsolete.
Moving Beyond the “Lab-to-Vial” Era
Current CAR-T therapy, while revolutionary, is a logistical and financial nightmare for many patients. This new breakthrough addresses the three biggest hurdles of traditional treatment:
| Feature | Traditional CAR-T Therapy | The New UCSF Method |
| Location | Extracted and engineered in a lab | Engineered directly inside the body |
| Cost | $400,000 – $500,000 | Significantly lower (Vaccine-like) |
| Preparation | Weeks of waiting + Chemotherapy | Immediate “Off-the-shelf” application |
| Patient Toll | Requires “clearing” bone marrow | Bypasses harsh pre-treatment |
The Science: The “Dual-Particle” Safety Switch
The biggest risk of engineering cells inside the body is “off-target” effects—accidentally altering the wrong cells. To solve this, the team developed a dual-particle system:
-
Precision Targeting: Large DNA sequences are integrated at a specific site in human T cells.
-
Activation Lock: The new DNA only activates once it is correctly placed within the T cell.
-
Success in Testing: The method successfully treated aggressive leukemia, multiple myeloma, and solid tumors in “humanized” mice.
“This could be the beginning of a big wave of new therapies that will be truly transformational and save a lot of lives,” said Justin Eyquem, senior author and associate professor of medicine at UCSF.
What’s Next?
While the results in mouse models are historic, the goal is to refine this into a therapy as accessible as a common vaccine. This would allow hospitals to treat patients immediately upon diagnosis, rather than waiting weeks for lab-grown cells to be shipped across the country.
